Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Primer for advisory panels

This article was originally published in The Tan Sheet

Executive Summary

CHPA's Scientific Affairs Committee is looking into ways to help improve the advisory committee review process. The SAC is working on "a document that sort of takes...frequently asked questions, and lays out some of the basics as a primer for advisory committee members," according to Committee Chair Ed Hemwall (J&J/Merck Consumer Pharmaceuticals). SAC would seek FDA endorsement of the document and would then provide it to advisory panel members prior to meetings. The document has not yet been drafted, but its purpose would be to "make sure that committee members understand going into the room the fundamentals of OTC study," such as consumer behavior trials and advertising regulation, Hemwall said. The information would "perhaps help reduce some of the off-topic debate and uninformed speculation that often occurs at these meetings," he added...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel